Search results
Results from the WOW.Com Content Network
Aromatase inhibitors (AIs) are a class of drugs used in the treatment of breast cancer in postmenopausal women and in men, [1] [2] and gynecomastia in men. They may also be used off-label to reduce estrogen conversion when supplementing testosterone exogenously. They may also be used for chemoprevention in women at high risk for breast cancer.
Nonylphenol exposure has also been associated with breast cancer. [2] It has been shown to promote the proliferation of breast cancer cells, due to its agonistic activity on ERα (estrogen receptor α) in estrogen-dependent and estrogen-independent breast cancer cells.
During the 20-year study period, 8.5 percent of women who had lumpectomies died from breast cancer, nine percent of women who had mastectomies died from the disease, and 8.5 percent of women who ...
Advances in the understanding of the natural course of breast cancer as well as the development of systemic therapies allowed for the use of breast-conserving surgeries, however, the nomenclature of viewing non-surgical management from the viewpoint of the definitive surgery lends to two adjectives connected with treatment timelines: adjuvant ...
Some women with a high risk of breast cancer can be prescribed tamoxifen; the estrogen-blocking drug is used to treat breast cancer at high doses, but it can also be used at lower doses to reduce ...
Neoadjuvant chemotherapy is given before surgery to slow the growth of a fast-growing cancer or to shrink the size of a larger breast cancer. [1] It is frequently used to treat locally advanced cancers, cancers that at the time of diagnosis are too large to be removed by surgery, which can then be removed with less extensive surgery. [2]
Elacestrant was not McDonnell’s first attempt at bringing a breast cancer drug to market. In 1996, his lab developed a similar drug, etacstil, which was the first oral medication in this class ...
Discussions and decision should be made with the help of specialists who can use relevant information and statistical models to predict the individual lifetime risk of development of breast cancer. Undergoing a preventive mastectomy does not guarantee that breast cancer will not develop later, however, it reduces the risk by 90% in high risk women.